Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Alcalá Vicente C, Lacruz L, Gascón F, Carratalà S, Quintanilla-Bordás C, Sanz MT, Carcelén-Gadea M, Mallada J, Carreres J, Gabaldón Torres L, Dominguez JA, Cañizares E, Gil-Perotin S, Cubas L, Gasqué Rubio R, Castillo-Villalba J, Pérez-Miralles FC, Casanova B. Alcalá Vicente C, et al. Among authors: gascon f. Front Neurol. 2022 Oct 28;13:991596. doi: 10.3389/fneur.2022.991596. eCollection 2022. Front Neurol. 2022. PMID: 36388220 Free PMC article.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcalá C, Quintanilla-Bordás C, Gascón F, Sempere ÁP, Navarro L, Carcelén-Gadea M, Landete L, Mallada J, Cañizares E, Belenguer A, Carratalá S, Domínguez JA, Pérez-Miralles FC, Gil-Perotín S, Gasqué R, Cubas L, Castillo J, Casanova B. Alcalá C, et al. Among authors: gascon f. J Neurol. 2022 Jul;269(7):3676-3681. doi: 10.1007/s00415-022-10989-0. Epub 2022 Feb 2. J Neurol. 2022. PMID: 35107597
Escalation vs. Early Intense Therapy in Multiple Sclerosis.
Casanova B, Quintanilla-Bordás C, Gascón F. Casanova B, et al. Among authors: gascon f. J Pers Med. 2022 Jan 17;12(1):119. doi: 10.3390/jpm12010119. J Pers Med. 2022. PMID: 35055434 Free PMC article. Review.
Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Escribano BM, Muñoz-Jurado A, Caballero-Villarraso J, Valdelvira ME, Giraldo AI, Paz-Rojas E, Gascón F, Santamaría A, Agüera E, Túnez I. Escribano BM, et al. Among authors: gascon f. Mult Scler Relat Disord. 2022 Feb;58:103520. doi: 10.1016/j.msard.2022.103520. Epub 2022 Jan 11. Mult Scler Relat Disord. 2022. PMID: 35038645 Free article.
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.
Landete L, Pérez-Miralles F, García S, Belenguer A, Gascón F, Domínguez JA, Carcelén-Gadea M, Quintanilla-Bordás C, Navarro L, Gabaldón L, Casanova B. Landete L, et al. Among authors: gascon f. Front Neurol. 2021 Oct 29;12:727586. doi: 10.3389/fneur.2021.727586. eCollection 2021. Front Neurol. 2021. PMID: 34803877 Free PMC article.
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S, Castillo-Villalba J, Cubas-Nuñez L, Gasque R, Hervas D, Gomez-Mateu J, Alcala C, Perez-Miralles F, Gascon F, Dominguez JA, Casanova B. Gil-Perotin S, et al. Among authors: gascon f. Front Neurol. 2019 Sep 23;10:1008. doi: 10.3389/fneur.2019.01008. eCollection 2019. Front Neurol. 2019. PMID: 31608004 Free PMC article.
86 results